IT’S UNCLEAR, DUE TO CONFLICTING EVIDENCE. Aspirin probably shouldn’t be used for routine prevention because of its potential risks (strength of recommendation [SOR]: B, systematic review of inconsistent evidence). However, aspirin is likely to be effective for secondary prevention of colorectal adenomas (SOR: A, systematic review).
A systematic review conducted for the US Preventive Services Task Force (USPSTF) addressed the use of aspirin for primary prevention of colorectal carcinomas (CRC) and colorectal adenomas (CRA).
Pooled data from 2 randomized-controlled trials (RCTs) with a total of 61,947 patients showed no decrease in CRC incidence (relative risk [RR]=1.02; 95% confidence interval [CI], 0.84-1.25) with regular aspirin use (325 mg every other day for 5 years or 100 mg every other day for 10 years). Six cohort studies that followed a total of 231,252 patients did report a decrease in CRC incidence over 4 to 10 years (RR=0.78; 95% CI, 0.63-0.97).1
In a pooled analysis evaluating 2 primary prevention RCTs (the British Doctors Aspirin Trial and UK-TIA Aspirin Trial, total N=7588), aspirin was found to reduce the incidence of colorectal cancer (hazard ratio [HR]=0.74; 95% CI, 0.56-0.97; P=.02 overall; for aspirin given for 5 years or longer, HR=0.63; 95% CI, 0.47-0.85; P=.002). The effect was significant only at 10 to 14 years of follow-up (0 to 9 years: HR=0.92, 95% CI, 0.56-1.49, P=.73; 5 to 9 years: HR=1.08, 95% CI, 0.55-2.14, P=.83; 10 to 14 years: HR=0.51, 95% CI, 0.29-0.90, P=.02; 15 to 19 years: HR=0.70, 95% CI, 0.43-1.14, P=.15; ≥20 years: HR=0.90, 95% CI, 0.42-1.95, P=.79).2
Adverse effects, including stroke, are dose-dependent
The USPSTF review also summarized the harms associated with aspirin use. When aspirin was given for secondary prevention of stroke, the risk of hemorrhagic stroke was dose-dependent, varying from 0.3% to 1.1% (100 mg/d: 0.3%, 95% CI, 0.2%-0.4%; 100-325 mg/d: 0.3%, 95% CI, 0.2%-0.3%; 325 mg/d: 1.1%, 95% CI, 0.7%-1.5%).
Aspirin also was associated with an increased risk of gastrointestinal (GI) symptoms (odds ratio [OR]=1.7; 95% CI, 1.5-1.8), GI bleeding (RR=1.6-2.5), and hospitalization for GI bleeding (OR=1.9; 95% CI, 1.1-3.1). The risks of GI bleeding or perforation were dose-dependent.1